| By Rexam Pharma |
| Friday, 03 April 2009 |
 |
Controlled release mechanisms for drug delivery have been the focus of continuous improvement over the past 20 years. Subcutaneous implants present the advantages of reducing side effects and allowing continuous drug release over weeks - or even
|
|
months - in contrast to the rapid decline in medication blood levels which follows injections or pill intake. However fragile implants require new transfer technologies under the skin which should not be fully dependent on expertise of the medical staff to |
|
|
prevent improper use. Drug-delivery devices need to be simpler, safer, and, in a context of increased homecare treatment and self-administration, more intuitive and convenient.
About Rexam
Rexam Plc is a leading global consumer packaging company and a global leader in rigid plastic packaging. With 22,000 people in more than 20 countries, Rexam’s sales from ongoing operations are approximately £3.6 billion. Rexam Pharma is part of the Rexam group’s |
|
Plastic Packaging business. It specializes in rigid plastic packaging solutions, intricate drug delivery systems & medical devices for pharmaceutical, medical and biotech industries.
Want to read more?
Rexam Pharma New Technical Paper - Implanting new ideas into next generation depot syringes
Rexam Pharma Corporate Profile - Expert in drug delivery devices and plastic primary packaging
Rexam Annual Report
|
|
|
